Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionindoleamine 2,3-dioxygenase activity

IDO1 IDO2

4.21e-0521302GO:0033754
GeneOntologyMolecularFunctiontryptophan 2,3-dioxygenase activity

IDO1 IDO2

1.26e-0431302GO:0004833
DomainIDO

IDO1 IDO2

4.73e-0521292PF01231
DomainIndolamine_dOase

IDO1 IDO2

4.73e-0521292IPR000898
DomainIDO_1

IDO1 IDO2

4.73e-0521292PS00876
DomainIDO_2

IDO1 IDO2

4.73e-0521292PS00877
DomainKRAB

ZNF845 ZNF484 ZNF780B ZFP57 ZNF772 ZNF112 ZNF235 ZNF773 ZNF766 ZNF615

1.93e-0435812910PS50805
DomainKRAB

ZNF845 ZNF484 ZNF780B ZFP57 ZNF772 ZNF112 ZNF235 ZNF773 ZNF766 ZNF615

1.93e-0435812910PF01352
DomainZF_ZZ_2

DYTN ZZEF1 MIB1

2.43e-04181293PS50135
DomainZF_ZZ_1

DYTN ZZEF1 MIB1

2.43e-04181293PS01357
DomainZZ

DYTN ZZEF1 MIB1

2.43e-04181293PF00569
DomainKRAB

ZNF845 ZNF484 ZNF780B ZFP57 ZNF772 ZNF112 ZNF235 ZNF773 ZNF766 ZNF615

2.46e-0436912910SM00349
DomainKRAB

ZNF845 ZNF484 ZNF780B ZFP57 ZNF772 ZNF112 ZNF235 ZNF773 ZNF766 ZNF615

2.51e-0437012910IPR001909
Domain-

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

2.54e-04679129143.30.160.60
DomainTF_AF4/FMR2

AFF2 AFF3

2.81e-0441292IPR007797
DomainAF-4

AFF2 AFF3

2.81e-0441292PF05110
DomainZnf_ZZ

DYTN ZZEF1 MIB1

2.88e-04191293IPR000433
DomainZnF_ZZ

DYTN ZZEF1 MIB1

2.88e-04191293SM00291
Domainzf-C2H2

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

3.13e-0469312914PF00096
DomainZnf_C2H2/integrase_DNA-bd

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

3.17e-0469412914IPR013087
DomainZnf_C2H2

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 TRIM23 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

4.46e-0480512915IPR007087
DomainDUF1785

PIWIL2 AGO4

4.67e-0451292SM01163
DomainARM-type_fold

NBEAL1 ZYG11B TRIP12 ITPR2 NOP9 NF1 TTI1 ATM TBCD

5.85e-043391299IPR016024
DomainArgoL1

PIWIL2 AGO4

6.97e-0461292PF08699
DomainArgoL1

PIWIL2 AGO4

6.97e-0461292IPR014811
DomainZINC_FINGER_C2H2_2

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

9.41e-0477512914PS50157
DomainZINC_FINGER_C2H2_1

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

9.64e-0477712914PS00028
DomainZnf_C2H2-like

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

1.21e-0379612914IPR015880
DomainPIWI

PIWIL2 AGO4

1.29e-0381292PS50822
DomainPTB

EPS8L2 TNS1

1.29e-0381292IPR013625
DomainPiwi

PIWIL2 AGO4

1.29e-0381292SM00950
DomainPiwi

PIWIL2 AGO4

1.29e-0381292PF02171
DomainPTB

EPS8L2 TNS1

1.29e-0381292PF08416
DomainPiwi

PIWIL2 AGO4

1.29e-0381292IPR003165
DomainZnF_C2H2

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

1.40e-0380812914SM00355
Domainzf-C2H2_6

ZNF845 ZNF780B ZNF521 PRDM5 ZNF773 ZSCAN10 ZNF766 ZNF615

1.53e-033141298PF13912
DomainPAZ

PIWIL2 AGO4

1.65e-0391292PS50821
DomainPAZ

PIWIL2 AGO4

1.65e-0391292SM00949
DomainPAZ

PIWIL2 AGO4

1.65e-0391292PF02170
DomainPAZ_dom

PIWIL2 AGO4

1.65e-0391292IPR003100
Domain-

TCTE1 LRRC75B NAIP CHAD ZYG11B LRRIQ4 SHOC2 LRRC8D

1.76e-0332112983.80.10.10
DomainL_dom-like

TCTE1 LRRC75B NAIP CHAD ZYG11B LRRIQ4 SHOC2 LRRC8D

2.01e-033281298IPR032675
Pubmed

Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.

CISD1 MINK1 AFF3 DENND11 ITPR2 TRIM16 NF1 AGO4 PRKD1 DDX41 TNS1 PDE7B PALLD ARHGAP21 GOLGA2

2.06e-069101321536736316
Pubmed

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.

NF1 TTI1 ATM TBCD

3.25e-0627132423027611
Pubmed

ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.

ZDHHC11B ZDHHC11

1.43e-052132228331227
Pubmed

Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19.

IDO1 IDO2

1.43e-052132234859884
Pubmed

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.

ATM TP53BP1

1.43e-052132227613518
Pubmed

ATM and 53BP1 regulate alternative end joining-mediated V(D)J recombination.

ATM TP53BP1

1.43e-052132239083600
Pubmed

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses.

IDO1 IDO2

1.43e-052132232973768
Pubmed

IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.

IDO1 IDO2

1.43e-052132225541686
Pubmed

Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells.

IDO1 IDO2

1.43e-052132232384638
Pubmed

Cooperative and indispensable roles of endothelin 3 and KIT signalings in melanocyte development.

EDN3 KIT

1.43e-052132215768389
Pubmed

The Clinical and Molecular Assessment of Iranian Families with Severe Congenital Neutropenia, Identification of HYOU1 and SHOC2 as Potential Novel Gene Defects.

HYOU1 SHOC2

1.43e-052132235822684
Pubmed

53BP1 is limiting for NHEJ repair in ATM-deficient model systems that are subjected to oncogenic stress or radiation.

ATM TP53BP1

1.43e-052132223858098
Pubmed

Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.

IDO1 IDO2

1.43e-052132233777052
Pubmed

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

IDO1 IDO2

1.43e-052132217671174
Pubmed

Phosphorylation of the DNA damage repair factor 53BP1 by ATM kinase controls neurodevelopmental programs in cortical brain organoids.

ATM TP53BP1

1.43e-052132239226322
Pubmed

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.

TET2 KIT

1.43e-052132223074272
Pubmed

Indoleamine 2,3-Dioxygenase 2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation.

IDO1 IDO2

1.43e-052132232752186
Pubmed

Identification of the novel Ido1 imprinted locus and its potential epigenetic role in pregnancy loss.

IDO1 IDO2

1.43e-052132230403776
Pubmed

Negative cell cycle regulation and DNA damage-inducible phosphorylation of the BRCT protein 53BP1.

ATM TP53BP1

1.43e-052132211042216
Pubmed

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

NF1 KIT

1.43e-052132218984156
Pubmed

Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.

NF1 KIT

1.43e-052132212393498
Pubmed

IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity.

IDO1 IDO2

1.43e-052132227470005
Pubmed

Testis-specific hnRNP is expressed in colorectal cancer cells and accelerates cell growth mediating ZDHHC11 mRNA stabilization.

ZDHHC11B ZDHHC11

1.43e-052132235384384
Pubmed

S1219 residue of 53BP1 is phosphorylated by ATM kinase upon DNA damage and required for proper execution of DNA damage response.

ATM TP53BP1

1.43e-052132218996087
Pubmed

NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.

NF1 ATM

1.43e-052132231664505
Pubmed

Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling.

IDO1 IDO2

1.43e-052132230374077
Pubmed

Indoleamine-2,3-dioxygenase-1 is a molecular target for the protective activity of mood stabilizers against mania-like behavior induced by d-amphetamine.

IDO1 IDO2

1.43e-052132231760073
Pubmed

Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation.

TET2 KIT

1.43e-052132229364877
Pubmed

Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection.

IDO1 IDO2

1.43e-052132221990421
Pubmed

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans.

IDO1 IDO2

1.43e-052132231134053
Pubmed

The role of ATM and 53BP1 as predictive markers in cervical cancer.

ATM TP53BP1

1.43e-052132222323184
Pubmed

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis.

IDO1 IDO2

1.43e-052132234589873
Pubmed

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.

TET2 KIT

1.43e-052132227391574
Pubmed

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients.

IDO1 IDO2

1.43e-052132235045867
Pubmed

The mouse Laf4 gene: exon/intron organization, cDNA sequence, alternative splicing, and expression during central nervous system development.

AFF2 AFF3

1.43e-052132212079280
Pubmed

IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

IDO1 IDO2

1.43e-052132224489090
Pubmed

Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors.

IDO1 IDO2

1.43e-052132221835273
Pubmed

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2.

IDO1 IDO2

1.43e-052132225394548
Pubmed

Investigation of the kynurenine pathway in Indoleamine 2, 3 dioxygenase deficient mice with inflammatory arthritis.

IDO1 IDO2

1.43e-052132223417792
Pubmed

Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.

TET2 KIT

1.43e-052132224788138
Pubmed

Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.

IDO1 IDO2

1.43e-052132231844921
Pubmed

Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1.

IDO1 IDO2

1.43e-052132224875753
Pubmed

Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients.

IDO1 IDO2

1.43e-052132227106797
Pubmed

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

TET2 KIT

1.43e-052132229467326
Pubmed

53BP1, an activator of ATM in response to DNA damage.

ATM TP53BP1

1.43e-052132215279780
Pubmed

The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

IDO1 IDO2

1.43e-052132224391212
Pubmed

IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma.

IDO1 IDO2

1.43e-052132230843276
Pubmed

Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis.

IDO1 IDO2

1.43e-052132222895526
Pubmed

Issues with the Specificity of Immunological Reagents for Murine IDO1.

IDO1 IDO2

1.43e-052132226959176
Pubmed

IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

IDO1 IDO2

1.43e-052132224402311
Pubmed

Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice.

TTF2 EPS8L2 SETX SHOC2 ARFIP1 TRIP12 PARP4 NF1 BRD4 ATM DDX41

1.46e-055821321120467437
Pubmed

A central chaperone-like role for 14-3-3 proteins in human cells.

TET2 KIF13B SETX MINK1 TRIP12 KIAA1671 NF1 AMOT PRRC2C BRD4 DDX41 PALLD ARHGAP21

2.58e-058611321336931259
Pubmed

USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma.

MYO7B MINK1 TRIP12 DHX15 FAT2 CEP250 UTP14C

3.30e-05234132736243803
Pubmed

Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.

IDO1 IDO2

4.28e-053132223786539
Pubmed

DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1.

ATM TP53BP1

4.28e-053132212447390
Pubmed

SNM1A acts downstream of ATM to promote the G1 cell cycle checkpoint.

DCLRE1B ATM

4.28e-053132218848520
Pubmed

Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage.

ATM TP53BP1

4.28e-053132222621922
Pubmed

Knockdown of PKD1 in normal human epidermal keratinocytes increases mRNA expression of keratin 10 and involucrin: early markers of keratinocyte differentiation.

IVL PRKD1

4.28e-053132218259765
Pubmed

ATM gene variants in patients with idiopathic perifoveal telangiectasia.

CFB ATM

4.28e-053132218502988
Pubmed

ZDHHC19 localizes to the cell membrane of spermatids and is involved in spermatogenesis†.

ZDHHC11B ZDHHC11

4.28e-053132234897408
Pubmed

Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

NF1 KIT

4.28e-053132210620616
Pubmed

An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation.

CR1 CFB

4.28e-053132220660348
Pubmed

Endothelin 3 induces skin pigmentation in a keratin-driven inducible mouse model.

EDN3 KIT

4.28e-053132217611578
Pubmed

The kynurenine pathway contributes to long-term neuropsychological changes in experimental pneumococcal meningitis.

IDO1 IDO2

4.28e-053132224844751
Pubmed

Endogenous hSNM1B/Apollo interacts with TRF2 and stimulates ATM in response to ionizing radiation.

DCLRE1B ATM

4.28e-053132218468965
Pubmed

Serum levels and activity of indoleamine2,3-dioxygenase and tryptophanyl-tRNA synthetase and their association with disease severity in patients with chronic kidney disease.

IDO1 IDO2

4.28e-053132223651343
Pubmed

ATM Localization and Heterochromatin Repair Depend on Direct Interaction of the 53BP1-BRCT2 Domain with γH2AX.

ATM TP53BP1

4.28e-053132226628370
Pubmed

Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in the maintenance of G(2)/M checkpoint arrest.

ATM TP53BP1

4.28e-053132220421415
Pubmed

Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage.

ATM TP53BP1

4.28e-053132221361779
Pubmed

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

NF1 KIT

4.28e-053132228296713
Pubmed

An X-to-autosome retrogene is required for spermatogenesis in mice.

KIT UTP14C

4.28e-053132215258580
Pubmed

Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity.

TET2 BRD4

4.28e-053132229662175
Pubmed

53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage.

ATM TP53BP1

4.28e-053132214695167
Pubmed

Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX.

ATM TP53BP1

4.28e-053132212697768
Pubmed

Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.

IDO1 IDO2

4.28e-053132227316339
Pubmed

Utp14b: a unique retrogene within a gene that has acquired multiple promoters and a specific function in spermatogenesis.

KIT UTP14C

4.28e-053132217291484
Pubmed

Calcium-mediated histone modifications regulate alternative splicing in cardiomyocytes.

NF1 PRKD1

4.28e-053132225368158
Pubmed

A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival.

ATM TP53BP1

4.28e-053132211756551
Pubmed

Functional characterization of the AFF (AF4/FMR2) family of RNA-binding proteins: insights into the molecular pathology of FRAXE intellectual disability.

AFF2 AFF3

4.28e-053132221330300
Pubmed

Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation.

IDO1 IDO2

4.28e-053132230760924
Pubmed

ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress.

ATM TP53BP1

4.28e-053132225262557
Pubmed

Neurofibromin as a regulator of melanocyte development and differentiation.

NF1 KIT

4.28e-053132218089649
Pubmed

Munc18b is an essential gene in mice whose expression is limiting for secretion by airway epithelial and mast cells.

STXBP2 KIT

4.28e-053132222694344
Pubmed

SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.

EDN3 KIT

4.28e-053132228880927
Pubmed

Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression.

TET2 SETX ZDBF2 TRIP12 DHX15 KIAA2012 PALLD

8.50e-05272132731010829
Pubmed

p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics.

CR1 KIT

8.54e-054132219124833
Pubmed

Human PTIP facilitates ATM-mediated activation of p53 and promotes cellular resistance to ionizing radiation.

ATM TP53BP1

8.54e-054132215456759
Pubmed

Homeostatic regulation of germinal stem cell proliferation by the GDNF/FSH pathway.

KIT UTP14C

8.54e-054132211900972
Pubmed

TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.

SPZ1 BRD4

8.54e-054132230154425
Pubmed

ZDHHC11 modulates innate immune response to DNA virus by mediating MITA-IRF3 association.

ZDHHC11B ZDHHC11

8.54e-054132229429998
Pubmed

Analysis of melanocyte precursors in Nf1 mutants reveals that MGF/KIT signaling promotes directed cell migration independent of its function in cell survival.

EDN3 NF1

8.54e-054132211401406
Pubmed

Membrane protein Crry maintains homeostasis of the complement system.

CR1 CFB

8.54e-054132218684964
Pubmed

Aryl hydrocarbon receptor control of a disease tolerance defence pathway.

IDO1 IDO2

8.54e-054132224930766
Pubmed

Low levels of endogenous or X-ray-induced DNA double-strand breaks activate apoptosis in adult neural stem cells.

ATM TP53BP1

8.54e-054132226303202
Pubmed

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.

IDO1 IDO2

8.54e-054132233671892
Pubmed

Mammalian Rif1 contributes to replication stress survival and homology-directed repair.

ATM TP53BP1

8.54e-054132219948482
Pubmed

The CysLT2R receptor mediates leukotriene C4-driven acute and chronic itch.

CYSLTR1 KIT

8.54e-054132233753496
Pubmed

Timeline and distribution of melanocyte precursors in the mouse heart.

EDN3 KIT

8.54e-054132218444965
Pubmed

Structure of the Human TELO2-TTI1-TTI2 Complex.

TTI1 ATM

8.54e-054132234838521
Pubmed

Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase.

NF1 KIT

8.54e-054132221037083
CytobandEnsembl 112 genes in cytogenetic band chr2q33

NBEAL1 DYTN ZDBF2 ANKRD44 KIAA2012

3.30e-042051325chr2q33
Cytoband18q11.2

ZNF521 CHST9 MIB1

3.43e-0447132318q11.2
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

ZNF845 ZNF484 ZNF780B ZFP57 ZNF521 ZNF772 ZNF112 ZNF235 PRDM5 ZNF773 ZSCAN10 ZNF665 ZNF766 ZNF615

9.03e-06718881428
GeneFamilyZinc fingers ZZ-type|Lysine acetyltransferases

DYTN ZZEF1 MIB1

8.62e-051888391
GeneFamilyAF4/FMR2 family|Super elongation complex

AFF2 AFF3

1.40e-0448821145
GeneFamilyArgonaute/PIWI family

PIWIL2 AGO4

6.43e-048882408
GeneFamilyAF4/FMR2 family|Super elongation complex

AFF2 AFF3

8.25e-0498821280
ToppCellLPS-IL1RA-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT DISP1

1.86e-06194132743f92b0533e26633dc94cce554045d641ef8fd76
ToppCellLPS-IL1RA-Endothelial-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT DISP1

1.86e-0619413271d39d968730a7e85b6161c1c8a6bd38afe9bcad7
ToppCell10x5'-lymph-node_spleen-Mast-Mast_cells|lymph-node_spleen / Manually curated celltypes from each tissue

AFF2 ZNF521 PRDM5 KIT TNS1 PALLD

1.10e-051681326650ad3ea52577887885d82457dbc04202ce3eb34
ToppCell10x5'-lymph-node_spleen-Mast|lymph-node_spleen / Manually curated celltypes from each tissue

AFF2 ZNF521 PRDM5 KIT TNS1 PALLD

1.10e-051681326e58ffbb57c81967766755c3f6f347b158a39cb0d
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-DC-DC3-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

IDO1 NBEAL1 MINK1 KIAA1671 ARHGAP31 PALLD

1.48e-051771326d34b086a5931d7f1737a504952d51c47693e91a8
ToppCellILEUM-inflamed-(7)_Lymphatics|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)

ZNF521 KIAA1671 TIE1 AMOT SCN4B TNS1

1.90e-051851326d711dd2e91cfee723dae1ccb2b910b8cf3becc3b
ToppCelldroplet-Heart-nan-3m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PKHD1L1 ITPR2 TIE1 SACS ARHGAP31 PRRC2C

1.96e-0518613260ae5fbe9f210cb25092394267e1d3d6ed05627b8
ToppCellControl-Endothelial-Endothelial-Alv_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 ARHGAP21

2.02e-051871326ea9d34bcd3bd1f36745846309ede349773de501a
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

IDO1 AFF3 ZNF521 TIE1 ARHGAP31 DISP1

2.02e-051871326f3397dbc23b6c2f24e2c1ba887d8f9aef3ee01a1
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Activated_Gen_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

CYSLTR1 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT

2.02e-051871326dffa8447c2f3fdacf39a7258c6b4e81a25245041
ToppCellLPS-antiTNF-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TRIM16 TIE1 KIT

2.08e-051881326789d1be574e693d7bdd488f3c72c6df788e47b47
ToppCellRA-10._Endothelium_II|RA / Chamber and Cluster_Paper

PKHD1L1 ITPR2 KIAA1671 TIE1 ARHGAP31 PDE7B

2.14e-051891326c81787a8c662db5d7814c583dd64562857629e81
ToppCellLPS_only-Endothelial-Endothelial-Alv_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 DISP1

2.21e-051901326474cbbab8f3b0a6881fa6c92edb78e43999f9ab0
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT

2.21e-051901326a3c6eec6df052105ab78b7e3c78f94218d5912eb
ToppCellLPS-antiTNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 DISP1

2.34e-051921326c618ede75dce3988c87a5b8f98d8e94e1dd66efd
ToppCellLPS-IL1RA+antiTNF-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT

2.34e-05192132604f5a2e3dd6beff027b89d66eefdd92036e041af
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT

2.34e-051921326c07d7b40b2aa4eb27ac85801c014a656e2fd01dc
ToppCellLPS-antiTNF-Endothelial-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT

2.41e-05193132602f633b016ab19bfa65bfd0cf32f000549a62148
ToppCellLPS-antiTNF-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31 KIT

2.41e-0519313265122b1ffba42de190061be34ecdc6176f84e56a3
ToppCell10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig-C|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ZNF845 RNF19A ZNF235 NOP9 ZNF665 TP53BP1

2.48e-0519413266be74e4ba631b0c46cef2c580553f4c1ed29579e
ToppCellLPS_only-Endothelial|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ZNF521 KIAA1671 TIE1 ARHGAP31 KIT DISP1

2.48e-05194132658f069efdefa0366033764446b9d6ffd4a17807e
ToppCellLPS_only-Endothelial-Endothelial|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ZNF521 KIAA1671 TIE1 ARHGAP31 KIT DISP1

2.48e-051941326bfd92ec75facb0ba55c31e5f2e089d983b3d0169
ToppCellmLN-(5)_Dendritic_cell-(53)_Lymphoid_DC|mLN / shred on region, Cell_type, and subtype

AFF2 IDO1 IDO2 SCN4B KIT PALLD

2.78e-051981326da84c76afe835aeee39da04b63c03549218b5d91
ToppCellmLN-Dendritic_cell-Lymphoid_DC|mLN / Region, Cell class and subclass

AFF2 IDO1 IDO2 SCN4B KIT PALLD

2.78e-0519813263965a9f1e8a51a196e5349aaca5fa5ed1cd8ee92
ToppCell(04)_Interm._basal>secr.-(2)_GFP_FOXI1|(04)_Interm._basal>secr. / shred by cell type by condition

SETX IDO1 TRIP12 PRRC2C BRD4 KIT

2.86e-05199132653ca3861f9e00dab3f3fbefb0837857ee39ab084
ToppCellmLN-Mast_cell-Mast|mLN / Region, Cell class and subclass

ZNF521 ZNF112 TIE1 ZDHHC11 KIT PALLD

2.94e-05200132681ea6e7a3940277751faf9097b30198159998c7b
ToppCellmild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

TET2 SETX TRIP12 ANKRD44 PRRC2C ATM

2.94e-05200132612f1685ce8f218433068e090c9d839cd5a1910bf
ToppCellmLN-Mast_cell|mLN / Region, Cell class and subclass

ZNF521 ZNF112 TIE1 ZDHHC11 KIT PALLD

2.94e-0520013269a5f1d99d8d160923d4d0fbbf9ad48a26f8a4fad
ToppCellmLN-(7)_Mast_cell-(70)_Mast|mLN / shred on region, Cell_type, and subtype

ZNF521 ZNF112 TIE1 ZDHHC11 KIT PALLD

2.94e-052001326a6c258cae678be581b1d85cf3446c65c34b13499
ToppCellmLN-(7)_Mast_cell|mLN / shred on region, Cell_type, and subtype

ZNF521 ZNF112 TIE1 ZDHHC11 KIT PALLD

2.94e-05200132613bca944fbdbc0be6687eca82c62a4d231ab94f0
ToppCell343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1|343B / Donor, Lineage, Cell class and subclass (all cells)

ZDBF2 TTC13 ATM ITPRIPL1 TAFAZZIN

8.21e-0514913252a7f71da51c85e04de2123164914122480e60d66
ToppCellnormal_Lymph_Node-Myeloid_cells-CD163+CD14+_DCs|Myeloid_cells / Location, Cell class and cell subclass

CYSLTR1 ZDBF2 TTI1 ZNF615 ATM

8.21e-051491325a34d095b8e0fe59d69d84e4fd2fe4ccb82f92e4f
ToppCell3'_v3-bone_marrow-Lymphocytic_Invariant-Inducer-like-ILC3|bone_marrow / Manually curated celltypes from each tissue

LRRC75B AFF3 EVC ZNF773 KIT

8.21e-051491325d7f1069f70f3cad6d3700ee2041ed1d4cb7c49ab
ToppCell356C-Lymphocytic-NK_cells-NK_cell_D3|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

LRRC75B IDO1 MYO3B KIT PDE7B

8.48e-051501325580ed7733857402345f43ca2623f72cdd1edf22c
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-Z|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

NAIP DENND11 ITPR2 ANKRD44 ATM

8.48e-0515013256c39e73a0b05d4b26589f333ce13924e3d373b8d
ToppCellChildren_(3_yrs)-Immune-mast_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

KIF13B AFF2 TTI1 KIT PDE7B

8.75e-051511325bbf735c6433c3fc2feedb24ed6f48c51d545fb60
ToppCell367C-Lymphocytic-ILC-ILC-3|367C / Donor, Lineage, Cell class and subclass (all cells)

ZNF845 TRMT2B THAP9 CEP250 TBCD

9.31e-0515313259d64aadbb4bb28469af1d728457b431e21577429
ToppCell10x5'-bone_marrow-Lymphocytic_Invariant-Inducer-like-ILC3|bone_marrow / Manually curated celltypes from each tissue

LRRC75B HDX SORCS1 PRKD1 KIT

9.89e-05155132583430a64c2cb5ad29caa3dacba76c28dd204ac40
ToppCellNS-moderate-d_07-13-Myeloid-Mast_cell|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

SLC4A8 AFF2 ZNF521 TIE1 KIT

1.02e-04156132517c38d3b03fc38cb125cf0d165b2fd694cd88edd
ToppCell5'-Adult-Appendix-Hematopoietic-B_cells-Cycling_B_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

AFF2 AFF3 CFAP20DC MYO3B ATM

1.02e-041561325203ef22eb76bd2b829b027c30af0557080f4006c
ToppCellsaliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

TCTE1 SLC4A8 DENND11 SACS TTC13

1.02e-041561325a5930b455e5c8586c43c50106ab4d8a1e5e9e3d6
ToppCell367C-Myeloid-Macrophage-SPP1+_Macrophage_3|367C / Donor, Lineage, Cell class and subclass (all cells)

TMPPE OTOA TCTE1 HYOU1 ZW10

1.08e-0415813250559cc032d0b518bb9e55aa3495f5573bd8e87dd
ToppCellNS-critical-LOC-Myeloid-Basophil|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

SORCS1 TIE1 DPEP3 MBD5 KIT

1.15e-0416013258a4746463ca1976f7d6de803496c851249ced797
ToppCellMild-Lymphoid-Plasma|Mild / Condition, Lineage, Cell class and cell subclass

AFF3 ZNF521 PKHD1L1 PRKD1 PDE7B

1.15e-0416013257fdb849f5caf5a127a2582326215e11f8eb4fa0e
ToppCellMild-Lymphoid-Plasma-|Mild / Condition, Lineage, Cell class and cell subclass

AFF3 ZNF521 PKHD1L1 PRKD1 PDE7B

1.15e-041601325aa79848913910c01249d6cacf4ed53ec0e4f5c3d
ToppCellfacs-Skin-nan-24m-Epithelial-bulge_keratinocyte|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PIWIL2 AMOT KIAA2012 TNS1 PALLD

1.29e-0416413257a65c7a6dbe5fb9067f83efafbb7ec8206d79325
ToppCell356C-Lymphocytic-NK_cells-NK_cell_D3|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

LRRC75B IDO1 MYO3B KIT PDE7B

1.33e-041651325a379fa981db51bec01adea7b1e55e133e15ec383
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

IDO1 ANKRD44 IDO2 ARHGAP31 DISP1

1.36e-04166132563dc58864268b4e7779e4c45155022556fc634f9
ToppCellCOPD-Lymphoid-ILC_B|Lymphoid / Disease state, Lineage and Cell class

CYSLTR1 AFF3 ARHGAP31 KIT PDE7B

1.36e-041661325e2cad1db536d5ad5a34c337c19b5e7d1a2851552
ToppCell368C-Fibroblasts-Fibroblast-C_(Myofibroblast)|368C / Donor, Lineage, Cell class and subclass (all cells)

SWT1 ZNF235 PRDM5 NMNAT3 SCN4B

1.44e-0416813251bc6a1915d48f547385ed4f44e118bcc8a4a7b6c
ToppCell368C-Fibroblasts-Fibroblast-C_(Myofibroblast)-|368C / Donor, Lineage, Cell class and subclass (all cells)

SWT1 ZNF235 PRDM5 NMNAT3 SCN4B

1.44e-04168132569f534de0f9a293047bea03cb1b78551087a8df5
ToppCellControl-Lymphoid-ILC_B|Lymphoid / Disease state, Lineage and Cell class

CYSLTR1 AFF3 ARHGAP31 KIT PDE7B

1.44e-041681325d7118d39253ed9790908b850088ebfc5a86f4065
ToppCell3'_v3-GI_small-bowel-Lymphocytic_T_CD8-Tnaive/CM_CD8|GI_small-bowel / Manually curated celltypes from each tissue

OTOA ZNF772 CR1 ITPR2 KIAA1671

1.44e-041681325c51244b4bdbfd961e2725306aa9cb25dd66d58bd
ToppCelltumor_Lymph_Node_/_Brain-T/NK_cells-Exhausted_Tfh|T/NK_cells / Location, Cell class and cell subclass

RNF19A CYSLTR1 CFAP20DC MEIOC PDE7B

1.48e-041691325625788d86f0ceebcf2653a251db1f1a9f9746d29
ToppCellCOVID-19-lung-MAST|lung / Disease (COVID-19 only), tissue and cell type

SLC4A8 ANKRD44 PARP4 KIT PDE7B

1.52e-041701325e90f18e5462381b38e918442b38b1c8105291908
ToppCellmetastatic_Brain-Myeloid_cells-CD207+CD1a+_LCs|Myeloid_cells / Location, Cell class and cell subclass

IDO1 CYSLTR1 CHAD AMOT SCN4B

1.61e-04172132538d17e769fe8eac8b57b820490d4ddd969243ee7
ToppCellSubstantia_nigra-Endothelial-ENDOTHELIAL_STALK-Flt1_1-Endothelial_Stalk.Flt1.Gkn3_(Gkn3)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EPS8L2 IDO1 CHST9 CFB

1.69e-049313244eca07c288fe15531a685522c61746671c1c87fb
ToppCellSubstantia_nigra-Endothelial-ENDOTHELIAL_STALK-Flt1_1-Endothelial_Stalk.Flt1.Gkn3_(Gkn3)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EPS8L2 IDO1 CHST9 CFB

1.69e-04931324312291db0fab96952017f9faf2057c28f3719556
ToppCellSubstantia_nigra-Endothelial-ENDOTHELIAL_STALK-Flt1_1-Endothelial_Stalk.Flt1.Gkn3_(Gkn3)--|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EPS8L2 IDO1 CHST9 CFB

1.69e-049313248f65381291fc92b56bf0fc2caac013a54560737b
ToppCell10x5'-GI_small-bowel-Mast|GI_small-bowel / Manually curated celltypes from each tissue

AFF2 ZNF521 KIT TNS1 PALLD

1.70e-041741325e94c980b25edfd0e8598c416828801fcc00e8ead
ToppCell10x5'-GI_small-bowel-Mast-Mast_cells|GI_small-bowel / Manually curated celltypes from each tissue

AFF2 ZNF521 KIT TNS1 PALLD

1.70e-04174132505525bf0a2bde2be4f7c147b17a24530ce8819e0
ToppCellP03-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

COL6A3 TIE1 KIT TNS1 PALLD

1.75e-041751325282f09bbdfa70d93b3f66591dcfb84c5ee0268c7
ToppCellControl-Neuronal_cells-Neuronal_cells|Control / group, cell type (main and fine annotations)

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

1.79e-04176132598c07d26ba0dc0fe15ca0ea81f633d4591782bd1
ToppCellControl-Neuronal_cells|Control / group, cell type (main and fine annotations)

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

1.79e-041761325c29d09ecf0eb17f767d78af4b7f2e7725c967ff8
ToppCellCOVID-19-lung-MAST|COVID-19 / Disease (COVID-19 only), tissue and cell type

SLC4A8 ANKRD44 PARP4 KIT PDE7B

1.79e-041761325473c45a381ca109207d66ed1635668b391ea0e1f
ToppCellCV-Severe-7|CV / Virus stimulation, Condition and Cluster

LRRC75B HYOU1 RNF19A ZNF235 ANKRD44

1.79e-0417613253de0c7d77210049e5616db21eed1490a17a5ec2d
ToppCellBAL-Mild-cDC_3|Mild / Compartment, Disease Groups and Clusters

CYSLTR1 ZYG11B ITPR2 TTC13 ZNF615

1.79e-041761325f9b0c3ced391e7ebe6b242d3f12ba14741f88d22
ToppCellPrimary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L3_LINC00507_CTXN3|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

CHST9 ITPR2 SCN4B PRKD1 PDE7B

1.84e-04177132596d639407f79669f3990138793d157b94273581c
ToppCellwk_15-18-Epithelial-PNS-Schwann_precursor|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

KIF13B CHAD SORCS1 NF1 SACS

1.84e-0417713255357359e6c2161a37f39a6b3b78449f5cbc327d1
ToppCellCV-Severe-7|Severe / Virus stimulation, Condition and Cluster

KIF13B LRRC75B HYOU1 RNF19A ZNF235

1.84e-04177132582fdd6185b368f54f03de389427cbe3071d21a99
ToppCellAdult-Endothelial-endothelial_cell_of_bronchial_vessel-D175|Adult / Lineage, Cell type, age group and donor

ZNF521 KIAA1671 TIE1 KIT TBCD

1.84e-041771325c9f269765c7d5d29caab75910e51645606ed562e
ToppCell5'-Adult-LargeIntestine-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ZNF521 ACOT6 PKHD1L1 TIE1 PDE7B

1.84e-041771325b1775e05c28883a15c56628028770bc59d3233fb
ToppCellTCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Mucinous_Colon_Adenocarcinoma-10|TCGA-Colorectal / Sample_Type by Project: Shred V9

NAIP ZNF521 EVC CR1 ARHGAP31

1.94e-041791325cc079ba015326dccde955c5eafa3e4a2e40de192
ToppCellmetastatic_Brain-Myeloid_cells-CD207+CD1a+_LCs|metastatic_Brain / Location, Cell class and cell subclass

IDO1 CYSLTR1 CHAD ITPR2 SCN4B

1.99e-04180132551727cb66fe7a7709453f7026e0ff3d6c93d5aa5
ToppCelldroplet-Kidney-nan-3m-Epithelial-Epcam____podocyte|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

KIF13B TCTE1 EDN3 IVL PALLD

1.99e-04180132535c73670da90cb6924e822a2426d13a675685f09
ToppCellnormal_Pleural_Fluid-Myeloid_cells-CD1c+_DCs|Myeloid_cells / Location, Cell class and cell subclass

IDO1 AFF3 IDO2 AMOT PRKD1

2.04e-041811325cc7ae1221a28bc404138a7efee0ad08a19cc3d86
ToppCellControl-Endothelial-Endothelial-Activated_Alv_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31

2.15e-041831325e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCellFetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.26e-041851325f9f48251bc33eb6bf2cff580d1a3207d21450aa0
ToppCellfacs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-brain_pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

COL6A3 XIRP1 SCN4B TNS1 PALLD

2.26e-04185132538486b69c48dc5e1c4e1488208fa8954a973eccb
ToppCellCOVID-19-Neuronal_cells-Neuronal_cells|COVID-19 / group, cell type (main and fine annotations)

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.26e-0418513254a095829992b39856a73bdfac03ee68b9aa0d3b8
ToppCellCOVID-19-Neuronal_cells|COVID-19 / group, cell type (main and fine annotations)

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.26e-04185132536ce23893915f5c380cca39b2c33a516edf31c3a
ToppCellfacs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-Pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

COL6A3 XIRP1 SCN4B TNS1 PALLD

2.26e-0418513253c28b5ceba3cfdb6f7e32d5b42e03b6a81a7a658
ToppCell368C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)

NAIP DENND11 PARP4 NOP9 MIB1

2.32e-04186132577bebf576eb9b96ecb4fefb8a82a31aaaa917fc0
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

IDO1 AFF3 ANKRD44 IDO2 ITPRIPL1

2.32e-041861325305f1726b8b5add32f1c29c74991ff34f42e0da7
ToppCellfacs-Lung-24m-Mesenchymal-fibroblast-alveolar_fibroblast-alveolar_fibroblast_l1|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

COL6A3 PRDM5 EDN3 CFB PDE7B

2.32e-041861325827f2f2ddde315d1e5970dd56f906c555ec699af
ToppCellTCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9

SETX NBEAL1 TAS2R38 PHC3 PARP4

2.32e-04186132503db813598b67b1e08f759758a1c2023396921fa
ToppCell368C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)

NAIP DENND11 PARP4 NOP9 MIB1

2.32e-04186132513bc41c60fd628af31899a5e8b480e06cc4781be
ToppCelltumor_Lymph_Node_/_Brain-Myeloid_cells-Undetermined|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass

OTOA ZNF521 TIE1 TTI1 KIT

2.37e-04187132555d5b21517c89736592982af40fd4cd64be62a3c
ToppCell368C-Lymphocytic-NK_cells-NK_cell_D3|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

KIF13B TTF2 ZFP57 TIE1 TTI1

2.37e-041871325c667fae6440dc98072b584f203d00f0fb1cb2f21
ToppCell368C-Lymphocytic-NK_cells-NK_cell_D3|368C / Donor, Lineage, Cell class and subclass (all cells)

KIF13B TTF2 ZFP57 TIE1 TTI1

2.43e-041881325ecc2364d946f97ae0212fd6739960c9fc75e4919
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial-Alv_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 TIE1 ARHGAP31 DISP1

2.43e-04188132573f6ec915934154f435a376cb274b058ff7c5f35
ToppCellEndothelial-endothelial_cell_of_lymph_vessel|World / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.43e-04188132580910dcbb51990f2baed240f319456c0d3fa2065
ToppCellChildren_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel|Children_(3_yrs) / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.43e-041881325c2805232618a7b6f844d34e37ad458a9923dbfe1
ToppCellChildren_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.43e-0418813252db80767903703e7e0a1a37c598f7877a909ee94
ToppCellFetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.49e-0418913250d18ea72bd58d32a8ab9a61cf97f5786642f804b
ToppCellLPS_only-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 KIT

2.49e-041891325e82211b9dc7540e7a183be2cbcfae39fdf503949
ToppCellControl-Endothelial-Endothelial-Alv_Gen_Intermediate|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

AFF3 ZNF521 KIAA1671 TIE1 ARHGAP31

2.49e-0418913255d7ae1ead7f4fbaeec26f651833c9c2106e1e4d1
ToppCellFetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.49e-04189132555a1776a4ce049959b3f13a43744c7314bc1f00a
ToppCellChildren_(3_yrs)-Endothelial-endothelial_cell_of_lymph_vessel-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

ZNF521 PKHD1L1 KIAA1671 TIE1 PDE7B

2.55e-0419013256e6ce6dd549d1c38cfef5b3f8be06ab01ce344b7
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DCDC1 EVC CHST9 MYO3B PRKD1

2.55e-0419013253fc9e18c7441c0ae8cda65753cc42d0520f4e116
Diseaserenal cell carcinoma

MYO7B LRRIQ4 ITPR2 ATM

3.03e-05421254EFO_0000681
DiseaseSystemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease

TET2 KIT

1.06e-0441252C1301365
Diseasemyeloproliferative neoplasm (is_implicated_in)

TET2 DDX41

1.06e-0441252DOID:2226 (is_implicated_in)
Diseasequinolinate measurement

IDO1 IDO2

3.69e-0471252EFO_0800175
DiseaseNeoplasm Recurrence, Local

TET2 IDO1 KIT

6.07e-04391253C0027643
DiseasePeripheral T-Cell Lymphoma

TET2 ATM

7.84e-04101252C0079774
Diseasemale infertility (implicated_via_orthology)

TCTE1 KIT

1.35e-03131252DOID:12336 (implicated_via_orthology)
Diseasetrimethylamine-N-oxide measurement

ITPR2 TTC13

1.57e-03141252EFO_0010541
Diseasecoronary artery disease

TET2 COL6A3 NBEAL1 CYSLTR1 DCLRE1B CFB STXBP2 KIF4B TNS1 PALLD ARHGAP21 ABCG8 TBCD

1.69e-03119412513EFO_0001645
DiseaseRASopathy

SHOC2 NF1

1.80e-03151252cv:C5555857
Diseaseoral squamous cell carcinoma (is_marker_for)

TET2 NAIP ATM

2.45e-03631253DOID:0050866 (is_marker_for)
Diseasepolychlorinated biphenyls measurement

ZNF521 MBD5 PALLD

2.68e-03651253EFO_0007042
Diseaseresponse to ketamine

EVC SORCS1 KIAA1671

3.17e-03691253EFO_0009748
DiseaseBRCAX breast cancer

ITPR2 PDE7B

3.22e-03201252EFO_0009443

Protein segments in the cluster

PeptideGeneStartEntry
IQNSPNLHVFHLKCN

NAIP

1151

Q13075
TKAAHNNSENIPLHK

AFF3

931

P51826
VLSPQDHHQQLVAHA

AMOT

61

Q4VCS5
LNQHAVVSPPALHNA

BRD4

851

O60885
HPNAKVLLHIATEDN

AZIN1

146

O14977
TNHSNQNHLVGIPKN

AFF2

86

P51816
TLPKIEQSQHLFQAH

ARFIP1

286

P53367
KCVAHVRQHNQLLPN

ABCG8

146

Q9H221
EEHNHQSLVPLEKAQ

ACOT6

301

Q3I5F7
PQALAKAVQIHHDTQ

AGO4

841

Q9HCK5
KHVHLENNRLNQLPS

CHAD

271

O15335
NQVVQLHPSTVLDHK

DHX15

716

O43143
AAHQIVQLIRKHPQH

DCLRE1B

161

Q9H816
FLHPVQHIQAQEKIG

DISP1

1356

Q96F81
IVKHFIQRHPINQGN

NBEAL1

936

Q6ZS30
CRGNPQNQVLLHKHL

ITPR2

1246

Q14571
HEAPSQEQKNLAAIQ

PRDM5

86

Q9NQX1
QKQVPAHARDFHINL

CFB

731

P00751
AVENHLEQRLHQPQK

OTOA

91

Q7RTW8
HFLQNKVDPNIVLHA

DCDC1

656

M0R2J8
LPEHQQKVLNHLSPD

TCTE1

101

Q5JU00
LQVFHQIHDHVNPKA

IDO1

211

P14902
HLQGQLQTLAAHPIA

NOP9

351

Q86U38
VAILQNLHHPGVVNL

PRKD1

631

Q15139
LHIPVQRQVAHCKNA

HDX

151

Q7Z353
HNNNTFLKHLENPPT

KIAA1671

711

Q9BY89
NHPLGMNQLQALHVK

LETMD1

241

Q6P1Q0
NNKEQIHPHTLFTPL

KIT

511

P10721
SPKIHQRNDPQHVND

LRRIQ4

11

A6NIV6
NKLPQLIDAHQLQAH

IDO2

61

Q6ZQW0
QKLDQANHAPHTLTV

FAT2

1616

Q9NYQ8
NQPFLIKTNHHLANL

PDE7B

221

Q9NP56
PAVTIKLHLNQNGDH

COMMD2

146

Q86X83
QHFLKANTEPRANLH

KIAA2012

641

Q0VF49
QLIYHLTPHSKQQQG

LRRC75B

116

Q2VPJ9
FQKIQHSITAQDHQP

NUTF2

61

P61970
NEKNNALQTPLHVAA

ANKRD44

936

Q8N8A2
QHSGPQKLLHIAQEL

FGD3

151

Q5JSP0
LNSIQKNHVHIANPD

PARP4

61

Q9UKK3
QNHHSKSPVDVLQIF

PARP4

401

Q9UKK3
PQSNVSLLDQHQHLK

DDX41

81

Q9UJV9
HQKQGALREQLQVHI

GOLGA2

206

Q08379
PPSKVSHHQLILQQQ

PHC3

316

Q8NDX5
LQKHIQNPSAAELVH

EPS8L2

331

Q9H6S3
QTPLHIAVNKGHLQV

MIB1

531

Q86YT6
NQDLAVPHNRKSHPQ

PALLD

246

Q8WX93
VNLFQHLVLNPKAHS

ITPRIPL1

516

Q6GPH6
HLVLNPKAHSQAVEE

ITPRIPL1

521

Q6GPH6
LNHVLHVVKNLGQSN

ATM

991

Q13315
QHLLGKQADNPHVAL

HYOU1

101

Q9Y4L1
VLHQDPHELQLNQSK

GNRHR

241

P30968
GNNAHENPKEVAIHL

CR1

2001

P17927
DQQSKQALDLHHPKL

EDN3

201

P14138
LLDQVNPKGVPHHAQ

DYTN

311

A2CJ06
PHHAQARLLKKQLNQ

DYTN

321

A2CJ06
DNQNVKTHHDHLQPL

DENND11

336

A4D1U4
HPQIVNLLKSVHNGA

COL6A3

1006

P12111
TQQRNNLEALPHSHK

CEP250

2116

Q9BV73
PNHHLAGLINQIQAS

MBD5

776

Q9P267
PHTAELNHLKQQVQQ

KIF4B

346

Q2VIQ3
NPSLHENLKQAVLPH

EVC

136

P57679
QNGHQATHLEVTKQP

DPEP3

441

Q9H4B8
NPENHDIANEVFKHL

SACS

4341

Q9NZJ4
LQNLQHLHITGNKVD

LRRC8D

751

Q7L1W4
QQQQQRDPEAHIKHL

MINK1

376

Q8N4C8
DAVNKVLRNHNIKPH

MAP3K5

1136

Q99683
KHIVNHAVVNEDPNA

KIF13B

351

Q9NQT8
IQLTHFQKLSEPLNH

TAS2R38

76

P59533
NSNLTPQQKIDELHH

MEIOC

211

A2RUB1
VQSNHLKNIPEKHSQ

TRMT2B

186

Q96GJ1
VKSIPANSHLVNHLN

TRIM42

131

Q8IWZ5
HSLNQHLQALLTPDK

NBPF7P

141

P0C2Y1
HLQALLTPDKHDNSQ

NBPF7P

146

P0C2Y1
DLAQQINLSPKQHHS

PIWIL2

516

Q8TC59
HSEQHPSQKDLQQLK

PKDREJ

1551

Q9NTG1
CHVKNPKENNLQHHA

SCN4B

131

Q8IWT1
PKENNLQHHATIFLQ

SCN4B

136

Q8IWT1
HNFPTVQHQELAKAQ

PRRC2C

2491

Q9Y520
HQDLSHIQQPAAVVA

SETX

2581

Q7Z333
AHNQLEHLPKEIGNC

SHOC2

246

Q9UQ13
HESKHPAFAKQQINL

SEM1

46

Q6ZVN7
HAVAPLQEIKQNLHT

PROSER3

171

Q2NL68
HHQNEKKRNNLIPIV

SLC4A8

221

Q2Y0W8
QVGQPKHLEQQEKHL

IVL

496

P07476
RAQHKAIPAVHFIND

SWT1

441

Q5T5J6
ENIHQIKQTVPIHAA

CFAP20DC

201

Q6ZVT6
EKIQEHITNQNPKFH

CHST9

71

Q7L1S5
NLHIQKDNPKIVHAF

CISD1

46

Q9NZ45
PPQDNQTKNHVLVLH

CYSLTR1

176

Q9Y271
QSHLPELQQFQHEGK

ZNF665

146

Q9H7R5
HDQRHAGNKPIKDQL

ZNF845

126

Q96IR2
IRKIDDPLQHHLQNQ

ZNF615

81

Q8N8J6
DPLQHHLQNQSIQKS

ZNF615

86

Q8N8J6
LQPHIKDVLHQNFES

TTC13

481

Q8NBP0
EHFPNHQQLQKNCLL

ZYG11B

416

Q9C0D3
SLVQHLLAHAQDQKP

ZSCAN10

391

Q96SZ4
KRNIHAAAHQVQVLP

UTP14C

671

Q5TAP6
KRHQKIHQNQEPVDG

ZFP57

191

Q9NU63
QLNHIAEEHGNNGIK

RNF19A

791

Q9NV58
HLKTQAEQLHNHLQP

TAFAZZIN

246

Q16635
IRAKNVAQNPLKHHS

THAP9

846

Q9H5L6
HHPNIINLLGACKNR

TIE1

896

P35590
NLNEHLKQVHEAQDP

ZNF521

451

Q96K83
NLAKLIQHANVQAHS

STXBP2

421

Q15833
LNADPHNVVVLHNKG

TNS1

101

Q9HBL0
PKVAIKHVNLGNENH

ZDBF2

1131

Q9HCK1
ISPHNNQHFKICLAQ

NF1

386

P21359
CQKHAPINSAQHLDN

RRP8

136

O43159
AHKAQVQGLQGHQLE

ARHGAP31

926

Q2M1Z3
HLPNLQTHKENPVLD

TP53BP1

46

Q12888
NPLNEDLQHPIHVKN

PKHD1L1

3631

Q86WI1
NLIQHQKIHSNEKPF

ZNF780B

291

Q9Y6R6
NLIQHQKIHSNEKPF

ZNF780B

431

Q9Y6R6
PLFDRSKHAHVIQNQ

ZDHHC11

111

Q9H8X9
NVQQHQKQHCGEKPL

ZNF773

111

Q6PK81
SHFQDLQIVHTKEQP

ZNF112

456

Q9UJU3
NANEPHNVIILKHFT

ZZEF1

2266

O43149
NQCGKPLHHKQALIQ

ZNF484

226

Q5JVG2
PQNSNLNIHKKIHTG

ZNF484

366

Q5JVG2
QPHQVNIKLQSHLLT

TRIM16

106

O95361
LHHQKQGTLQEKPIQ

SPZ1

341

Q9BXG8
HLDEQAVQGLKQIHQ

TBCD

646

Q9BTW9
SLPNHQVIHTADKPN

ZNF766

201

Q5HY98
HQGHKHSVLEPEANQ

TRIM23

211

P36406
PLFDRSKHAHVIQNQ

ZDHHC11B

111

P0C7U3
PEEDSQHHQHKLLAQ

RPTN

651

Q6XPR3
IHTLNQNSVHFELKP

SORCS1

1061

Q8WY21
FNTHQLKCQLQRHPD

TRIP12

1261

Q14669
IKDQRPVNHLHQNSL

ARHGAP21

646

Q5T5U3
TVDQHLQFQKPSHQV

TET2

646

Q6N021
NLQVHQIIHTGEKPF

ZNF235

641

Q14590
QSLHQQVLNKHKQGP

XIRP1

1066

Q702N8
NLHQHQKQHSGEKPF

ZNF772

186

Q68DY9
EKVTQLLPQNVHSHN

TTF2

256

Q9UNY4
LQSHKNQLLPLAHQA

TTI1

896

O43156
LQKLPQLAAIHHNNC

ZW10

531

O43264
HVQPLHNENVKISAT

TMPPE

296

Q6ZT21
LQDQKHQNPVAKTRH

MYO3B

311

Q8WXR4
VHANNKAFLQPKNIH

MYO7B

531

Q6PIF6
QHNIHLAKEPVQNEI

NMNAT3

186

Q96T66